Patents by Inventor Harpreet Singh

Harpreet Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12156905
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: January 24, 2023
    Date of Patent: December 3, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 12150979
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: November 26, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Oliver Schoor, Andrea Mahr, Toni Weinschenk, Anita Wiebe, Jens Fritsche, Harpreet Singh
  • Patent number: 12152302
    Abstract: A method and apparatus for producing a gas distribution apparatus are described herein. More specifically, a method and apparatus for producing triple-channel gas distribution apparatus is described herein. The gas distribution apparatus described herein includes an upper plate, a middle plate, and a lower plate. The middle plate and the lower plate are machined before all of the upper plate, the middle plate, and the lower plate are bonded. Additional machining is then performed on the gas distribution apparatus. The gas distribution apparatus is used to distribute three or more process gases into a processing chamber.
    Type: Grant
    Filed: July 8, 2020
    Date of Patent: November 26, 2024
    Assignee: APPLIED MATERIALS, INC.
    Inventors: Kazuya Daito, Jallepally Ravi, Harpreet Singh
  • Patent number: 12144852
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: January 28, 2022
    Date of Patent: November 19, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Phillip Mueller, Julia Leibold, Valentina Goldfinger
  • Publication number: 20240350602
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: June 28, 2024
    Publication date: October 24, 2024
    Inventors: Andrea MAHR, Toni WEINSCHENK, Anita WIEBE, Oliver SCHOOR, Jens FRITSCHE, Harpreet SINGH
  • Patent number: 12121627
    Abstract: Embodiments of the present disclosure provide for structures including an alloy of calcium, strontium, and magnesium.
    Type: Grant
    Filed: September 27, 2022
    Date of Patent: October 22, 2024
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Michele Viola Manuel, Ida E. Svensson Berglund, Benjamin G. Keselowsky, Malisa Sarntinoranont, Harpreet Singh Brar, Hunter B. Henderson
  • Patent number: 12103984
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: October 1, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 12102670
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: January 14, 2022
    Date of Patent: October 1, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Phillip Mueller, Julia Leibold, Valentina Goldfinger
  • Publication number: 20240320406
    Abstract: Aspects of the present disclosure relate to improving runtime performance of equivalence checkers by a shift left process that uses an RTL lint tool to identify RTL code that can be a source of verification complexity for the downstream equivalence checker. The RTL code is further compared to a corresponding circuit model to determine a potential gate-level location of the potentially problematic RTL code. A weight can be calculated to represent a level of verification complexity that may be generated by the particular portion of the RTL code. Further, one or more recommendations can be generated by the RTL lint tool to prevent some of the verification complexity for the downstream equivalence checker.
    Type: Application
    Filed: March 24, 2023
    Publication date: September 26, 2024
    Inventors: Himanshu KATHURIA, Makarand PATIL, Rohit Kumar OHLAYAN, Paras Mal JAIN, Ila VERMA, Mohan MANGAL, Jaideep DUTT, Jaskaran Singh AJIMAL, Harpreet Singh ANAND
  • Patent number: 12097249
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: January 21, 2022
    Date of Patent: September 24, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Phillip Mueller, Julia Leibold, Valentina Goldfinger
  • Patent number: 12084486
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: September 10, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Heiko Schuster, Daniel Johannes Kowalewski, Oliver Schoor, Jens Fritsche, Toni Weinschenk, Harpreet Singh, Gisela Schimmack, Michael Roemer
  • Patent number: 12084522
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: September 10, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Publication number: 20240294602
    Abstract: A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide.
    Type: Application
    Filed: April 26, 2024
    Publication date: September 5, 2024
    Inventors: Andrea MAHR, Toni WEINSCHENK, Oliver SCHOOR, Jens FRITSCHE, Harpreet SINGH, Lea STEVERMANN
  • Patent number: 12076381
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: January 14, 2022
    Date of Patent: September 3, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Phillip Mueller, Julia Leibold, Valentina Goldfinger
  • Patent number: 12076379
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: July 2, 2021
    Date of Patent: September 3, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Colette Song, Linus Backert, Heiko Schuster, Daniel Johannes Kowalewski, Oliver Schoor, Jens Fritsche, Toni Weinschenk, Harpreet Singh
  • Publication number: 20240285738
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: April 26, 2024
    Publication date: August 29, 2024
    Inventors: Andrea MAHR, Toni WEINSCHENK, Anita WIEBE, Oliver SCHOOR, Jens FRITSCHE, Harpreet SINGH
  • Patent number: 12071458
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: November 18, 2021
    Date of Patent: August 27, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Andrea Mahr, Toni Weinschenk, Helen Hoerzer, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 12065471
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: September 17, 2021
    Date of Patent: August 20, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Colette Song, Heiko Schuster, Daniel Johannes Kowalewski, Oliver Schoor, Jens Fritsche, Toni Weinschenk, Harpreet Singh
  • Patent number: 12069042
    Abstract: The techniques disclosed herein enable improved security as well as more scalable and reliable job execution by utilizing granular security boundaries and certificate-based authentication for all communication within cloud-based platforms. To manage a cloud-based platform, a system receives a plurality of jobs and associated certificates at a first security boundary that are to be executed at various resource units within a second security boundary. The system then authenticates each certificate before transmitting each job to its respective resource unit for execution. In addition, the system is further configured to monitor active certificates for compromise and accordingly isolate various security boundaries in the event of a security breach. By isolating portions of the cloud-based platform within security boundaries, the system can mitigate the impact of security breaches. Furthermore, certificate-based authentication addresses performance constraints to enable more efficient and scalable job execution.
    Type: Grant
    Filed: November 5, 2021
    Date of Patent: August 20, 2024
    Assignee: MICROSOFT TECHNOLOGY LICENSING, LLC
    Inventors: Nidhi Verma, Roberta Cannerozzi, Brian Gregory O'Connor, Darius Snapkauskas, Le Chang, Harpreet Singh Miglani, Phillip Isaac Beish, Dylan Thomas Nunley
  • Patent number: 12064465
    Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
    Type: Grant
    Filed: October 1, 2021
    Date of Patent: August 20, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh